Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held Oct 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.

Download as PDF

Kiora Pharmaceuticals (NASDA: KPRX) will participate in a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of products in development. Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness. The 30 minute event will be held Wednesday, October 19, 2022 at 4:30 PM Eastern Time.


Webinar Title: Battling Blindness in Retinitis Pigmentosa: A Discussion of Disease & the Pipeline of Hope

Description: Retinitis pigmentosa is a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors, the light-sensing cells. To date, there is no cure for retinitis pigmentosa.

This webinar will provide an overview of the disease progression from diagnosis to blindness, and how patients’ lives are affected. More specifically, the panel of RP experts will discuss the landscape of investigational treatments with technologies ranging from gene and cell therapies to photoresponsive small molecules, including the patient, medical and industry perspectives.

Location & Time: Click here to join live on Oct 19, 2022 04:30 PM Eastern Time. A replay of the presentation will be available on the IR section of Kiora's website.

 

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis ("OPRA"). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Investor Contact

Francina Agosti, Ph.D.
(617) 546-0742
fagosti@reportablenews.com

Released September 28, 2022